Alcohol Use Disorder Treatment companies

Report ID: 3804
Published Date: Sep 09, 2025
Report Format: PDF, PPT

Buy Now

Alcohol Use Disorder Treatment Market Players:

One of the key strategies adopted by the companies involved in the alcohol use disorder treatment market is investing in new drug formulations. This is mainly done through upgrading the existing drugs and undergoing substantial clinical trials to explore their complete potential with funding activities. For instance, in March 2025, Tempero Bio, Inc. secured USD 70 million in Series B financing for advancing TMP-301 into Phase 2 trials for substance use disorders such as alcohol and cocaine use disorders, which was led by Aditum Bio, Khosla Ventures, and others. These investments, in addition to other strategic collaborations, are projected to influence significant market activities, maintaining healthy competition between the global players.

Some of the prominent players in the alcohol use disorder treatment market are:

Alkermes Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Teva Pharmaceutical Industries Ltd.
BioCorRx, Inc
Adial Pharmaceuticals
ADDEX THERAPEUTICS
Kinnov Therapeutics
Opiant Pharmaceuticals
Ethypharm
Omeros Corporation
Montisera Ltd.
Altimmune, Inc.,
BioCorRx Inc
Amygdala Neurosciences, Inc
Clearmind Medicine Inc.
DURECT Corporation
Adial Pharmaceuticals, Inc
Pear Therapeutics
Tempero Bio, Inc.

Browse key industry insights with market data tables & charts from the report:

Alcohol Use Disorder Treatment Market Size & Growth 2035

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of alcohol use disorder treatment is estimated at USD 1.43 billion.

The global alcohol use disorder treatment market size was more than USD 1.36 billion in 2025 and is anticipated to grow at a CAGR of over 6.1%, reaching USD 2.46 billion revenue by 2035.

North America alcohol use disorder treatment market will hold around 46% share by 2035, driven by the robust healthcare infrastructure and growing demand for AUD treatments.

Key players in the market include Teva Pharmaceutical Industries Ltd., BioCorRx, Inc, Adial Pharmaceuticals, ADDEX Therapeutics, Kinnov Therapeutics, Opiant Pharmaceuticals.